You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Claims for Patent: 12,161,628

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,161,628

Title:	Combination therapy
Abstract:	This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.
Inventor(s):	Jacqueline GIBBONS, Joyce MORDENTI, Michiel DE VRIES, Walter KRAUWINKEL, Taoufik Ouatas
Assignee:	Astellas Pharma Inc , Medivation Prostate Therapeutics LLC
Application Number:	US17/959,350
Patent Claims:	1. A method of treating prostate cancer in a patient to whom rifampin is administered, comprising co-administering to the patient a daily dose of 240 mg enzalutamide. 2. The method of claim 1, wherein the prostate cancer is castration-resistant prostate cancer. 3. The method of claim 1, wherein the prostate cancer is hormone-sensitive prostate cancer. 4. The method of claim 1, wherein the prostate cancer is metastatic prostate cancer. 5. The method of claim 4, wherein the prostate cancer is metastatic castration-resistant prostate cancer. 6. The method of claim 4, wherein the prostate cancer is metastatic hormone-sensitive prostate cancer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.